| A comparison of preferences for two GLP-1 products--liraglutide and exenatide--for the treatment of type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 21034377 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To use time trade-off (TTO) to compare patient preferences for profiles of two glucagon-like peptide (GLP-1) products for the treatment of type 2 diabetes (liraglutide and exenatide) that vary on four key attributes - efficacy (as measured by hemoglobin A(1C)), incidence of nausea, incidence of hypoglycemia, and dosing frequency (QD vs. BID) - and measure the contribution of those attributes to preferences. METHODS: A total of 382 people with T2DM were recruited to participate in an internet-based survey consisting of a series of health-related questions, a conjoint exercise and a set of time trade-off items. In the conjoint exercise, respondents were presented with eight pairs of hypothetical GLP-1 profiles, and completed a time-tradeoff exercise for each pair. RESULTS: The product profile representing liraglutide was preferred by 96% of respondents and resulted in significantly higher health utilities (0.038) than the product profile representing exenatide (0.978 vs. 0.94, p < 0.05). Estimated preference scores from the conjoint analysis revealed that efficacy measured by hemoglobin A(1C) is the most important attribute, followed by nausea, hypoglycemia, and dosing schedule. LIMITATIONS: On-line participants may not represent 'typical' type 2 diabetes patients, and brief product profiles represented results from clinical trials, not clinical practice CONCLUSION: Based on the four attributes presented, patients prefer liraglutide over exenatide. Preference is based on superior efficacy and less nausea more than less hypoglycemia and once-daily dosing. |
| | |
Authors:
|
Michael Polster; Elaine Zanutto; Susan McDonald; Christopher Conner; Mette Hammer |
Related Documents
:
|
8941507 - Coca chewing for exercise: hormonal and metabolic responses of nonhabitual chewers. 8833707 - Endogenous oploid peptides stimulate post-exercise insulin response to glucose in rats. 1186497 - The effect of somatostatin on plasma noradrenaline and plasma adrenaline concentrations... 1514617 - Metabolic regulation in peripheral tissues and transition to increased gluconeogenic mo... 9922897 - Fluid and electrolyte replacement in soccer. 17279097 - The incidence of post-race symptoms of upper respiratory tract infection in wheelchair ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-11-01 |
Journal Detail:
|
Title: Journal of medical economics Volume: 13 ISSN: 1941-837X ISO Abbreviation: J Med Econ Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-12-08 Completed Date: 2011-05-03 Revised Date: 2013-05-13 |
Medline Journal Info:
|
Nlm Unique ID: 9892255 Medline TA: J Med Econ Country: England |
Other Details:
|
Languages: eng Pagination: 655-61 Citation Subset: IM |
Affiliation:
|
National Analysts Worldwide, Philadelphia, PA 19103, USA. mpolster@nationalanalysts.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Diabetes Mellitus, Type 2 / drug therapy* Drug Administration Schedule Female Glucagon-Like Peptide 1 / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use Hemoglobin A, Glycosylated Humans Hypoglycemia / chemically induced Hypoglycemic Agents / administration & dosage, adverse effects, therapeutic use* Male Middle Aged Nausea / chemically induced Patient Preference* Peptides / administration & dosage, adverse effects, therapeutic use* Quality of Life Socioeconomic Factors Venoms / administration & dosage, adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Peptides; 0/Venoms; 141732-76-5/exenatide; 839I73S42A/liraglutide; 89750-14-1/Glucagon-Like Peptide 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
Next Document: The impact of pain on labor force participation, absenteeism and presenteeism in the European Union.